“Breaking News: MRK’s SNDA for Welireg Receives FDA’s Priority Tag for Rare Tumors”
Merck’s sNDA for Welireg Granted Priority Review by FDA for Treatment of Pheochromocytoma and Paraganglioma Introduction On May 26, 2025, the FDA will be making a crucial decision regarding Merck’s supplemental New Drug Application (sNDA) for Welireg. This medication is aimed at treating advanced cases of pheochromocytoma and paraganglioma, two rare neuroendocrine tumors that can…